Vimarsana
Biggest News Aggregation in the World

Page 27 - Confidence Interval News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Confidence Interval. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Confidence Interval Today - Breaking & Trending Today

Botulinum toxin effective in treating isolated or essential head tremor - Vimarsana News

Botulinum toxin effective in treating isolated or essential head tremor

1. In this randomized controlled trial, botulinum toxin was more effective than placebo in treating isolated or essential head tremor at 18 weeks follow-up. 2. Adverse events occurred more frequently in the botulinum toxin group including head and neck pain, posterior cervical weakness, and dysphagia. Evidence Rating Level: 1 (Excellent) Study Rundown: Essential tremor is

No Clear Evidence Acupuncture Provides Benefit in Chronic Spontaneous Urticaria - Vimarsana News

No Clear Evidence Acupuncture Provides Benefit in Chronic Spontaneous Urticaria

A randomized trial examining acupuncture in people with CSU suggests use of acupuncture could improve UAS7 scores in these patients, but investigators noted this failed to reach the threshold for significance.

Ceftobiprole non-inferior to daptomycin in treating Staphylococcus aureus bacteremia - Vimarsana News

Ceftobiprole non-inferior to daptomycin in treating Staphylococcus aureus bacteremia

1. In this randomized controlled trial, treatment of patients with complicated Staphylococcus aureus (S. aureus) bacteremia with ceftobiprole was non-inferior to treatment with daptomycin. 2. Secondary outcomes were consistent between the ceftobiprole and daptomycin treatment groups, including mortality, relapse, and microbiologic eradication. Evidence Rating Level: 1 (Excellent) Study Rundown: S. aureus is a leading cause of

U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) - Vimarsana News

U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)

The approval is based on the pivotal TRIDENT-1 trial, in which Augtyro successfully achieved a high objective response rate and durable response1 Augtyro adds to Bristol Myers Squibb’s growing...

AHA 2023 Data Highlights Potential of Acoramidis in ATTR-CM - Vimarsana News

AHA 2023 Data Highlights Potential of Acoramidis in ATTR-CM

Ahmad Masri, MD, MS, discusses new acoramidis data from the ATTRibute-CM trial at AHA 2023.